[Featured Stock] Hugel, Strong Performance with Record Q3 Earnings

Hugel is showing strong performance. The news of recording the highest quarterly earnings seems to have had an impact.

As of 3:04 PM on the 6th, Hugel was trading at 320,500 KRW, up 28,500 KRW (9.76%) from the previous trading day.

Hugel announced on the same day that it recorded consolidated third-quarter sales of 105.1 billion KRW, operating profit of 53.4 billion KRW, and net profit of 42.0 billion KRW.

Thanks to strong performance in the global market, sales and operating profit surpassed 100 billion KRW and 50 billion KRW respectively for the first time ever, achieving the highest quarterly figures in history. Compared to the same period last year, sales grew by 23.9%, and operating profit increased by 54.5%.

By product category, the botulinum toxin product ‘Botulax’ recorded sales of 64.7 billion KRW, an increase of about 41% compared to the same period last year. HA fillers (‘The Chaeum’, ‘Bylizen Skinbooster HA’) posted sales of 29.9 billion KRW. In the third quarter, sales in the European market grew by about 7%, showing steady performance in overseas markets.

Sales in the cosmetics sector (‘Wellage’, ‘Bylizen BR’) also grew strongly by 37.4%. The derma cosmetic brand Wellage additionally launched a new line called ‘Hyper Peptide’. The high-end cosmetic brand ‘Bylizen BR’ has been gradually expanding consumer touchpoints since its new launch in April. The absorbable suture brand ‘Blue Rose’ is also maintaining its growth trend.